213 related articles for article (PubMed ID: 19894778)
1. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer.
Murad YM; Clay TM
BioDrugs; 2009; 23(6):361-75. PubMed ID: 19894778
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.
Jurk M; Vollmer J
BioDrugs; 2007; 21(6):387-401. PubMed ID: 18020622
[TBL] [Abstract][Full Text] [Related]
3. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.
Murad YM; Clay TM; Lyerly HK; Morse MA
Expert Opin Biol Ther; 2007 Aug; 7(8):1257-66. PubMed ID: 17696823
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
Vollmer J; Krieg AM
Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma.
Gupta GK; Agrawal DK
BioDrugs; 2010 Aug; 24(4):225-35. PubMed ID: 20623989
[TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21.
Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH
Front Immunol; 2019; 10():179. PubMed ID: 30800129
[TBL] [Abstract][Full Text] [Related]
7. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
8. Single Stranded DNA Immune Modulators with Unmethylated CpG Motifs: Structure and Molecular Recognition by Toll-Like Receptor 9.
Fehér K
Curr Protein Pept Sci; 2019; 20(11):1060-1068. PubMed ID: 31470785
[TBL] [Abstract][Full Text] [Related]
9. TLR9 agonists: immune mechanisms and therapeutic potential in domestic animals.
Mutwiri G
Vet Immunol Immunopathol; 2012 Jul; 148(1-2):85-9. PubMed ID: 21700345
[TBL] [Abstract][Full Text] [Related]
10. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.
Vollmer J
Expert Opin Biol Ther; 2005 May; 5(5):673-82. PubMed ID: 15934842
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic potential of CpG oligodeoxynucleotides in veterinary species.
Manuja A; Manuja BK; Kaushik J; Singha H; Singh RK
Immunopharmacol Immunotoxicol; 2013 Oct; 35(5):535-44. PubMed ID: 23981003
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of Toll-like receptor 9 activation.
Krieg AM
Nat Rev Drug Discov; 2006 Jun; 5(6):471-84. PubMed ID: 16763660
[TBL] [Abstract][Full Text] [Related]
15. Common human Toll-like receptor 9 polymorphisms and haplotypes: association with atopy and functional relevance.
Berghöfer B; Frommer T; König IR; Ziegler A; Chakraborty T; Bein G; Hackstein H
Clin Exp Allergy; 2005 Sep; 35(9):1147-54. PubMed ID: 16164440
[TBL] [Abstract][Full Text] [Related]
16. CpG 7909: PF 3512676, PF-3512676.
Drugs R D; 2006; 7(5):312-6. PubMed ID: 16922592
[TBL] [Abstract][Full Text] [Related]
17. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo.
Schlaepfer E; Audigé A; von Beust B; Manolova V; Weber M; Joller H; Bachmann MF; Kundig TM; Speck RF
J Virol; 2004 Nov; 78(22):12344-54. PubMed ID: 15507621
[TBL] [Abstract][Full Text] [Related]
18. Antiinfective applications of toll-like receptor 9 agonists.
Krieg AM
Proc Am Thorac Soc; 2007 Jul; 4(3):289-94. PubMed ID: 17607015
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection.
Lv S; Wang J; Dou S; Yang X; Ni X; Sun R; Tian Z; Wei H
Hepatology; 2014 Feb; 59(2):385-94. PubMed ID: 23907803
[TBL] [Abstract][Full Text] [Related]
20. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]